Psilera Secures Funding to Enhance FTD Research
Psilera, an innovative biotechnology company, is on a mission to revolutionize at-home care for challenging neurological conditions, with a specific focus on frontotemporal dementia (FTD). Founded in 2019 by USF Alumni Chris Witsowski, Ph.D., and Jackie von Salm, Ph.D., the company is dedicated to transforming patient care.
Investment from USF Research Foundation
Recently, Psilera announced that it has received a $200,000 investment from the University of South Florida (USF) Research Foundation. This funding marks a continuation of the successful collaboration between Psilera and USF, and it will significantly advance their ongoing research into neurodegenerative disorders.
Focus on Innovative Therapies
Psilera's flagship candidate, PSIL-006, is an innovative therapy specifically designed to address the psychological challenges associated with frontotemporal dementia. FTD is a progressive condition that affects cognitive abilities and behavior, creating substantial difficulties for both patients and their families.
Commitment to Patient-Centered Research
Chris Witsowski, the CEO and co-founder of Psilera, expressed his pride in receiving support from the USF Research Foundation, emphasizing the strength of their partnership. He remarked, "USF has consistently encouraged companies like ours to push the boundaries of science for the benefit of patients. This investment allows us to further our patient-centered research efforts that can lead to meaningful change."
Support from USF Research Foundation Leadership
Dr. Sylvia Thomas, the President and CEO of the USF Research Foundation, shared her support, noting that Psilera's focus on patient-centered approaches holds great potential for enhancing the quality of life for many individuals and families affected by debilitating conditions.
Positive Preclinical Findings
Recent preclinical studies have yielded promising results, showing that PSIL-006 not only addresses psychiatric symptoms but also improves learning, memory, and normalizes sleep patterns in relevant models. This highlights its multifaceted potential in treating FTD and related disorders.
About Psilera
Psilera is at the forefront of developing groundbreaking therapeutics for neurological and neurodegenerative diseases. With a strong commitment to enhancing patient experiences through scientific progress, Psilera aims to make a significant impact on the lives of individuals facing these challenging medical conditions. They are paving the way for a new era of dedicated mental health treatment.
Frequently Asked Questions
What is Psilera's primary focus?
Psilera is dedicated to developing innovative therapies for neurological and neurodegenerative diseases, with a particular emphasis on improving patient care.
How much funding did Psilera receive from USF?
Psilera received a $200,000 investment from the USF Research Foundation to support its research initiatives.
What is PSIL-006?
PSIL-006 is Psilera's lead clinical candidate designed to alleviate the psychological symptoms associated with frontotemporal dementia.
Why is FTD significant to Psilera?
FTD is a debilitating condition that greatly affects cognition and behavior, making it a critical area where Psilera aims to create a substantial impact in patient care.
Who co-founded Psilera?
Psilera was co-founded by USF Alumni Chris Witsowski, Ph.D., and Jackie von Salm, Ph.D., in 2019.
